Latest Articles

LLTs Exposure Time and Major Vascular Risk Reduction

Meta Analysis of apoB Lowering and CV Risk Reduction Among Different LLTs

Galimberti F, et al. Poster presented at the 91st European Atherosclerosis Society congress (EAS) 2023.

LDL-C The Only Causal Risk Factor for ASCVD

Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia

LLTs and Antithrombotic Therapy in PAD

Lipid Management in Patients with Diabetes Mellitus

LDL-C Targets in Patients with Heterozygous Familial Hypercholesterolemia

Lipid-Lowering Therapy and Achievement of Lipid Targets ESC and EAS Guidelines

The role of the patient in Achieving LDL-C Target